Acute community-acquired bacterial sinusitis: the value of antimicrobial treatment and the natural history

Clin Infect Dis. 2004 Jan 15;38(2):227-33. doi: 10.1086/380641. Epub 2003 Dec 19.

Abstract

Two areas of investigation were reviewed: (1) placebo-controlled trials of antimicrobial treatment involving patients with a clinical diagnosis of acute community-acquired bacterial sinusitis (ACABS) for whom pre- and posttherapy sinus aspirate cultures were not performed, and (2) uncontrolled trials of antimicrobial treatment involving patients with ACABS for whom pre- and posttherapy sinus aspirate cultures were performed. The clinical diagnostic criteria in the controlled trials were not correlated with sinus aspirate culture results and, thus, were of questionable validity. Most of the populations probably included patients with viral rhinosinusitis. In 10 uncontrolled studies, the posttreatment, weighted, pooled mean bacterial resolution rate (+/- standard error) at 7-10 days, based on sinus aspirate culture results, was 91%+/-10%. In 9 controlled trials, the weighted pooled mean rate of clinical improvement (+/- standard deviation) at 7-14 days for placebo recipients was 52%+/-18%. In 1 controlled trial in which diagnosis was based on duration of unimproved illness, 57% of placebo recipients and 85.5% of treated patients were healthy or had improved by day 10. Additional studies of ACABS are needed.

MeSH terms

  • Acute Disease
  • Anti-Bacterial Agents / therapeutic use*
  • Bacterial Infections / drug therapy*
  • Bacterial Infections / ethnology
  • Community-Acquired Infections / drug therapy*
  • Community-Acquired Infections / ethnology
  • Humans
  • Natural History
  • Patient Compliance
  • Randomized Controlled Trials as Topic
  • Sinusitis / drug therapy*
  • Sinusitis / ethnology
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents